UY31285A1 - Vacunas - Google Patents
VacunasInfo
- Publication number
- UY31285A1 UY31285A1 UY31285A UY31285A UY31285A1 UY 31285 A1 UY31285 A1 UY 31285A1 UY 31285 A UY31285 A UY 31285A UY 31285 A UY31285 A UY 31285A UY 31285 A1 UY31285 A1 UY 31285A1
- Authority
- UY
- Uruguay
- Prior art keywords
- vaccines
- malaria
- circumesporozoite
- medicament
- protein
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 201000004792 malaria Diseases 0.000 abstract 2
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invencion se refiere al uso de un antígeno derivado de la proteína circumesporozoíto (CS) de Plasmodium falciparum que se expresa en la etapa preeritrocítica de la infeccion por malaria combinado con un adyuvante farmacéuticamente aceptable, en la fabricacion de un medicamento para vacunar bebés contra la malaria.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95544507P | 2007-08-13 | 2007-08-13 | |
US95733807P | 2007-08-22 | 2007-08-22 | |
US98280107P | 2007-10-26 | 2007-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31285A1 true UY31285A1 (es) | 2009-03-31 |
Family
ID=39870250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31285A UY31285A1 (es) | 2007-08-13 | 2008-08-11 | Vacunas |
Country Status (21)
Country | Link |
---|---|
US (1) | US9066899B2 (es) |
EP (1) | EP2190470B1 (es) |
JP (1) | JP5508266B2 (es) |
KR (1) | KR20100068390A (es) |
AP (1) | AP2010005166A0 (es) |
AR (1) | AR067905A1 (es) |
AU (1) | AU2008288508B2 (es) |
BR (1) | BRPI0815199A2 (es) |
CA (1) | CA2695477A1 (es) |
CL (1) | CL2008002361A1 (es) |
CR (1) | CR11307A (es) |
DO (1) | DOP2010000056A (es) |
ES (1) | ES2658347T3 (es) |
MA (1) | MA31693B1 (es) |
MX (1) | MX2010001752A (es) |
NZ (1) | NZ583150A (es) |
TR (1) | TR201802221T4 (es) |
TW (1) | TW200924791A (es) |
UY (1) | UY31285A1 (es) |
WO (1) | WO2009021931A1 (es) |
ZA (1) | ZA201001029B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2010005166A0 (en) | 2007-08-13 | 2010-02-28 | Glaxosmithkline Biolog Sa | Vaccines |
KR101616572B1 (ko) * | 2009-05-05 | 2016-05-11 | 카딜라 핼쓰캐어 리미티드 | 홍역-말라리아 조합 백신 |
JP5796011B2 (ja) | 2009-06-24 | 2015-10-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
EP3351266A1 (en) * | 2009-11-05 | 2018-07-25 | The United States of America as represented by the Secretary of the Navy | Plasmodium falciparum sporozoite and liver stage antigens |
EP2385107B1 (en) * | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
JP6293485B2 (ja) | 2010-09-27 | 2018-03-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | コンセンサス抗原コンストラクトおよびそれらから作製されるワクチン、ならびにそれらを使用するマラリアの治療方法 |
US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
CN102268093B (zh) * | 2011-06-27 | 2013-06-26 | 广东药学院 | 一种肝靶向肽与人干扰素a2b融合蛋白及其制备方法和应用 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
GB201416773D0 (en) * | 2014-09-23 | 2014-11-05 | Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford | Novel Methods For Including An Imune Response |
WO2016184784A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1 |
EP3947446A1 (en) | 2019-03-25 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
DE3280028D1 (en) | 1981-05-21 | 1989-12-28 | Wellcome Found | Protozoal antigen |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
GB9002512D0 (en) | 1990-02-05 | 1990-04-04 | 3I Res Expl Ltd | Polypeptides and dna encoding same |
GB9012580D0 (en) | 1990-06-06 | 1990-07-25 | Univ Nijmegen | Novel protein |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5198535A (en) | 1991-01-10 | 1993-03-30 | The United States Of America As Represented By The Secretary Of The Navy | Protective malaria sporozoite surface protein immunogen and gene |
DK0614465T3 (da) | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybridprotein mellem CS fra Plasmodium og HBsAg |
CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
JP4028593B2 (ja) | 1993-03-23 | 2007-12-26 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
ATE261322T1 (de) | 1997-03-29 | 2004-03-15 | Ji Hoon Park | Dauerinjektionsvorrichtung |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
ATE435661T1 (de) | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
WO2002077195A2 (en) | 2001-03-26 | 2002-10-03 | Walter Reed Army Institute Of Research | Plasmodium falciparum ama-1 protein and uses thereof |
AU2002360429A1 (en) | 2001-11-26 | 2003-06-10 | Avigen, Inc. | Methods for producing stocks of recombinant aav virions |
PL376792A1 (pl) | 2002-10-23 | 2006-01-09 | Glaxosmithkline Biologicals S.A. | Sposoby szczepienia przeciwko malarii |
EP1569674B1 (en) | 2002-11-12 | 2014-12-24 | Walter Reed Army Institute of Research | Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide |
GB0420634D0 (en) | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
US20080131461A1 (en) | 2004-10-14 | 2008-06-05 | Crucell Holland B.V. | Malaria Prime/Boost Vaccines |
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP1754717A1 (en) | 2005-08-19 | 2007-02-21 | Université de Lausanne | Antigenic peptides and their use |
AP2010005166A0 (en) | 2007-08-13 | 2010-02-28 | Glaxosmithkline Biolog Sa | Vaccines |
EP2945649B1 (en) * | 2013-01-22 | 2018-12-12 | Oxford University Innovation Limited | Composition and uses thereof |
-
2008
- 2008-08-11 AP AP2010005166A patent/AP2010005166A0/en unknown
- 2008-08-11 EP EP08787080.4A patent/EP2190470B1/en active Active
- 2008-08-11 KR KR1020107005518A patent/KR20100068390A/ko active IP Right Grant
- 2008-08-11 TR TR2018/02221T patent/TR201802221T4/tr unknown
- 2008-08-11 BR BRPI0815199 patent/BRPI0815199A2/pt not_active Application Discontinuation
- 2008-08-11 AR ARP080103497A patent/AR067905A1/es not_active Application Discontinuation
- 2008-08-11 TW TW097130604A patent/TW200924791A/zh unknown
- 2008-08-11 US US12/673,272 patent/US9066899B2/en active Active
- 2008-08-11 MX MX2010001752A patent/MX2010001752A/es active IP Right Grant
- 2008-08-11 CA CA2695477A patent/CA2695477A1/en active Pending
- 2008-08-11 JP JP2010520550A patent/JP5508266B2/ja active Active
- 2008-08-11 WO PCT/EP2008/060505 patent/WO2009021931A1/en active Application Filing
- 2008-08-11 AU AU2008288508A patent/AU2008288508B2/en not_active Ceased
- 2008-08-11 ES ES08787080.4T patent/ES2658347T3/es active Active
- 2008-08-11 NZ NZ583150A patent/NZ583150A/en not_active IP Right Cessation
- 2008-08-11 CL CL2008002361A patent/CL2008002361A1/es unknown
- 2008-08-11 UY UY31285A patent/UY31285A1/es unknown
-
2010
- 2010-02-11 ZA ZA2010/01029A patent/ZA201001029B/en unknown
- 2010-02-11 DO DO2010000056A patent/DOP2010000056A/es unknown
- 2010-03-08 MA MA32675A patent/MA31693B1/fr unknown
- 2010-03-10 CR CR11307A patent/CR11307A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20110212159A1 (en) | 2011-09-01 |
MX2010001752A (es) | 2010-03-10 |
JP5508266B2 (ja) | 2014-05-28 |
CR11307A (es) | 2010-05-24 |
BRPI0815199A2 (pt) | 2015-03-31 |
KR20100068390A (ko) | 2010-06-23 |
TW200924791A (en) | 2009-06-16 |
NZ583150A (en) | 2012-05-25 |
MA31693B1 (fr) | 2010-09-01 |
EP2190470A1 (en) | 2010-06-02 |
JP2010535836A (ja) | 2010-11-25 |
AU2008288508B2 (en) | 2014-05-01 |
AR067905A1 (es) | 2009-10-28 |
AP2010005166A0 (en) | 2010-02-28 |
EP2190470B1 (en) | 2017-12-13 |
US9066899B2 (en) | 2015-06-30 |
ES2658347T3 (es) | 2018-03-09 |
AU2008288508A1 (en) | 2009-02-19 |
CL2008002361A1 (es) | 2009-08-07 |
CN101820901A (zh) | 2010-09-01 |
DOP2010000056A (es) | 2010-07-31 |
CA2695477A1 (en) | 2009-02-19 |
ZA201001029B (en) | 2011-04-28 |
WO2009021931A1 (en) | 2009-02-19 |
TR201802221T4 (tr) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31285A1 (es) | Vacunas | |
UA93508C2 (en) | Anti-malaria vaccine | |
AR051023A1 (es) | Vacunas que contienen antigeno de plasmodium | |
EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
CL2014002415A1 (es) | Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11). | |
AR061894A1 (es) | Vacunas para malaria | |
DE122011100053I1 (de) | Influenza vakzinzusammensetzungen zur intradermaler verabreichung. | |
AR065523A1 (es) | Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones | |
CR10559A (es) | Vacuna de influenza | |
PT2121011E (pt) | Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe | |
MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
BR112012016048A2 (pt) | "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos". | |
CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
WO2006062637A3 (en) | Influenza vaccination | |
AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
UY31510A1 (es) | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
UY31574A1 (es) | Vacunas contra la malaria | |
NZ580603A (en) | Intradermal influenza vaccine | |
BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
BR112014012184A2 (pt) | vacina de malária | |
BRPI0800485B8 (pt) | vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose | |
WO2010064208A3 (en) | Msp2 antigenic peptides and their use | |
WO2010023452A3 (en) | Nematode vaccine |